Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Breast Cancer | Research article

Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer

Authors: Yingying Lin, Xusheng Zhou, Wei Peng, Jing Wu, Xiufeng Wu, Yan Chen, Zhaolei Cui

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Basic leucine zipper ATF-like transcription factor 2 (BATF2) has been reported to participate in the occurrence and development of some malignancies. Herein, we aimed to explore the expression pattern and clinical implications of BATF2 in breast cancer (BC).

Methods

We assessed the differences in BATF2 mRNA expression between cancerous and noncancerous tissues in BC using GEPIA and UALCAN data and in BATF2 protein expression pattern using Human Protein Atlas (HPA) data. BATF2 co-expression networks were analyzed in Coexpedia. The association between the differentially expressed BATF2 mRNA and BC prognosis was assessed using UALCAN, OSbrca, and GEPIA databases. In external validations, BATF2 protein expression in BC tissues was quantitated using a tissue microarray and immunohistochemistry (IHC) analysis, and BATF2 mRNA expression in serum and serum-derived exosomes of BC patients using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR).

Results

No difference in the BATF2 mRNA expression level was found between cancerous and noncancerous tissues in BC based on databases. There were low-to-moderate levels of increases in BATF2 protein expressions in BC cases from the HPA cohort. BATF2 mRNA expression was negatively correlated with androgen receptor (AR) and positively correlated with BRCA2 DNA repair associated (BRCA2), marker of proliferation Ki-67 (Mki67), and tumor protein p53 (TP53) expressions. Generally, BATF2 mRNA exhibited a non-significant association with BC prognosis; yet the subgroup analyses showed that triple-negative breast cancer (TNBC) patients with high BATF2 mRNA expressions had a longer overall survival (OS). Our IHC analysis revealed a positive rate of BATF2 protein expression of 46.90%, mainly located in the nucleus of cancer cells in BC, and the OS of BC patients with high BATF2 protein expressions was prolonged. The positive rates of BATF2 mRNA expressions in the serum and exosomes were 45.00 and 41.67%, respectively. Besides, the AUCs of serum and exosomal BATF2 mRNA for BC diagnosis were 0.8929 and 0.8869, respectively.

Conclusions

BC patients exhibit low-to-moderate expressions in BATF2 mRNA expression levels in cancerous tissues. The high BATF2 protein expression can be a potential indicator of a better BC prognosis. Serum and exosomal BATF2 mRNA levels also serve as promising noninvasive biomarkers for BC diagnosis.

Available only for authorised users

DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409–18. https://doi.org/10.3322/caac.20134.CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Coughlin SS. Epidemiology of breast Cancer in women. Adv Exp Med Biol. 2019;1152:9–29. https://doi.org/10.1007/978-3-030-20301-6_2.CrossRefPubMed

McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, et al. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. J Med Genet. 2018;55(9):571–7. https://doi.org/10.1136/jmedgenet-2018-105472.CrossRefPubMed

Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32. https://doi.org/10.1016/bs.pmbts.2017.07.002.CrossRefPubMed

Su ZZ, Lee SG, Emdad L, Lebdeva IV, Gupta P, Valerie K, et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci U S A. 2008;105(52):20906–11. https://doi.org/10.1073/pnas.0807975106.CrossRefPubMedPubMedCentral

Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol. 2013;13(7):499–509. https://doi.org/10.1038/nri3470.CrossRefPubMed

Huang Q, Yang Y, Li X, Huang S. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells. Tumour Biol. 2011;32(6):1191–7. https://doi.org/10.1007/s13277-011-0222-1.CrossRefPubMed

Dash R, Su ZZ, Lee SG, Azab B, Boukerche H, Sarkar D, et al. Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene. 2010;29(31):4412–23. https://doi.org/10.1038/onc.2010.194.CrossRefPubMed

10.

Liu ZB, Yang Y, Ye XG, Wang L, Tian PY, Zhang YY. Expression and significance of SARI and CCN1 in human colorectal carcinomas. Zhonghua Yi Xue Za Zhi. 2011;91(34):2397–401.PubMed

11.

Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011;128(4):771–7. https://doi.org/10.1002/ijc.25407.CrossRefPubMed

12.

Zhou RJ, Shi Z, Zhou K, Wang HD, Zhang GQ, Li XT, et al. Decreased SARI expression predicts poor prognosis of Chinese patients with non-small cell lung cancer. Int J Clin Exp Pathol. 2013;6(10):2056–63.PubMedPubMedCentral

13.

Han T, Wang Z, Yang Y, Shu T, Li W, Liu D, et al. The tumor-suppressive role of BATF2 in esophageal squamous cell carcinoma. Oncol Rep. 2015;34(3):1353–60. https://doi.org/10.3892/or.2015.4090.CrossRefPubMed

14.

Xie JW, Huang XB, Chen QY, Ma YB, Zhao YJ, Liu LC, et al. m (6) a modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling. Mol Cancer. 2020;19(1):114. https://doi.org/10.1186/s12943-020-01223-4.CrossRefPubMedPubMedCentral

15.

Wang C, Su Y, Zhang L, Wang M, You J, Zhao X, et al. The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. PLoS One. 2012;7(9):e38046. https://doi.org/10.1371/journal.pone.0038046.CrossRefPubMedPubMedCentral

16.

Desany B, Zhang Z. Bioinformatics and cancer target discovery. Drug Discov Today. 2004;9(18):795–802. https://doi.org/10.1016/S1359-6446(04)03224-6.CrossRefPubMed

17.

Gómez-López G, Valencia A. Bioinformatics and cancer research: building bridges for translational research. Clin Transl Oncol. 2008;10(2):85–95. https://doi.org/10.1007/s12094-008-0161-5.CrossRefPubMed

18.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. https://doi.org/10.1093/nar/gkx247.CrossRefPubMedPubMedCentral

19.

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, NY). 2017;19(8):649–58.CrossRef

20.

Yang S, Kim CY, Hwang S, Kim E, Kim H, Shim H, et al. COEXPEDIA: exploring biomedical hypotheses via co-expressions associated with medical subject headings (MeSH). Nucleic Acids Res. 2017;45(D1):D389–d396. https://doi.org/10.1093/nar/gkw868.CrossRefPubMed

21.

Yan Z, Wang Q, Sun X, Ban B, Lu Z, Dang Y, et al. OSbrca: a web server for breast Cancer prognostic biomarker investigation with massive data from tens of cohorts. Front Oncol. 2019;9:1349. https://doi.org/10.3389/fonc.2019.01349.CrossRefPubMedPubMedCentral

22.

Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11(1):6047. https://doi.org/10.1038/s41598-021-84787-5.CrossRefPubMedPubMedCentral

23.

Cui Z, Chen Y, Hu M, Lin Y, Zhang S, Kong L, et al. Diagnostic and prognostic value of the cancer-testis antigen lactate dehydrogenase C4 in breast cancer. Clin Chim Acta. 2020;503:203–9.CrossRef

24.

Cui Z, Li Y, Gao Y, Kong L, Lin Y, Chen Y. Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction. Aging. 2020;12(19):19455–67. https://doi.org/10.18632/aging.103879.CrossRefPubMedPubMedCentral

25.

Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3(1):26913. https://doi.org/10.3402/jev.v3.26913.CrossRefPubMed

26.

Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015;25(6):364–72. https://doi.org/10.1016/j.tcb.2015.01.004.CrossRefPubMed

27.

Safdar A, Tarnopolsky MA. Exosomes as Mediators of the Systemic Adaptations to Endurance Exercise. Cold Spring Harb Perspect Med. 2018;8(3):a029827.CrossRef

28.

Trotta T, Panaro MA, Cianciulli A, Mori G, Di Benedetto A, Porro C. Microglia-derived extracellular vesicles in Alzheimer’s disease: a double-edged sword. Biochem Pharmacol. 2018;148:184–92. https://doi.org/10.1016/j.bcp.2017.12.020.CrossRefPubMed

29.

Qin J, Xu Q. Functions and application of exosomes. Acta Pol Pharm. 2014;71(4):537–43. https://doi.org/10.1024/0040-5930/a000549.CrossRefPubMed

30.

Roe JK, Thomas N, Gil E, Best K, Tsaliki E, Morris-Jones S, et al. Blood transcriptomic diagnosis of pulmonary and extrapulmonary tuberculosis. JCI Insight. 2016;1(16):e87238. https://doi.org/10.1172/jci.insight.87238.CrossRefPubMedPubMedCentral

31.

Koussounadis A, Langdon SP, Um IH, Harrison DJ, Smith VA. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci Rep. 2015;5(1):10775. https://doi.org/10.1038/srep10775.CrossRefPubMedPubMedCentral

Title: Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer
Authors: Yingying Lin
Xusheng Zhou
Wei Peng
Jing Wu
Xiufeng Wu
Yan Chen
Zhaolei Cui
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08785-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database

Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model

ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes

The effects of physical activity on overall survival among advanced cancer patients: a systematic review and meta-analysis

Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis

Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer